Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: Clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8371-8379

  Thatcher, Nicholas ^a   Qian, Wendi ^a   Clark, Peter I ^a   Hopwood, Penelope ^a   Sambrook, Robert J ^a   Owens, Robert ^a   Stephens, Richard J ^a   Girling, David J ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BRONCHOPNEUMONIA; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FEVER; HEALTH STATUS; HUMAN; LETHARGY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MOUTH PAIN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTICEMIA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING; ADULT; AGED; COMPARATIVE STUDY; LUNG TUMOR; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PROSPECTIVE STUDY; SMALL CELL CARCINOMA; SURVIVAL; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; ETOPOSIDE; FEMALE; GREAT BRITAIN; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 33644671956     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.9969     Document Type: Article

References (40)

1. Hansen HH: Management of small-cell cancer of the lung. Lancet 339:846-849, 1992
2. Wolff AC, Ettinger DS, Neuberg D, et al: Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 13:1615-1622, 1995
3. Smith IE, Perren TJ, Ashley SA, et al: Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin Oncol 8:899-905, 1990
4. Thatcher N: Ifosfamide, carboplatin and etoposide (ICE) regimen in small cell lung cancer. Lung Cancer 9:S51-S69, 1993 (suppl 1)
5. Thatcher N, Lind M: Carboplatin in small cell lung cancer. Semin Oncol 17:40-48, 1990
6. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: A Hellenic Cooperative Oncology Group study. Ann Oncol 5:601-607, 1994
7. Thatcher N, Lind M, Stout R, et al: Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. Br J Cancer 60:98-101, 1989
8. Prendiville J, Longan P, Hicks F, et al: Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. Eur J Cancer 30A:2085-2090, 1994
9. Thatcher N, Girling DJ, Hopwood P, et al: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council multicenter randomized trial-Medical Research Council Lung Cancer Working Party. J Clin Oncol 18:395-404, 2000
10. Carney DN, Shepherd FA: Treatment of SCLC: Chemotherapy, in Hanson HH (ed): Textbook of Lung Cancer. London, United Kingdom, Marin Dunitz, 2000, pp 261-272
11. de Haes JC, van Knippenberg FC, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62:1034-1038, 1990
12. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
13. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994
14. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication 48. Geneva, Switzerland, World Health Organization, 1979
15. Cerny T, Blair V, Anderson H, et al: Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients. Int J Cancer 39:146-149, 1987
16. Rawson NSB, Peto J: An overview of prognostic factors in small cell lung cancer. Br J Cancer 61:597-604, 1990
17. Zigmond AS, Snaith RP: The hospital anxiety and depression scale Acta Psychiatr Scand 67:361-370, 1983
18. Stephens RJ, Hopwood P. Evaluation of the prognostic value of a simple patient-assessed functional impairment scale in lung cancer. Lung Cancer 29:271, 2000 (suppl 1; abstr 930)
19. Chute JP, Venzon D, Hankins L, et al: Outcome of patients with small cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72:901-912, 1997
20. Chute JP, Chen T, Feigal E, et al: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 17:794-1801, 1999
21. Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8-15, 2000
22. Sundstrom S, Bremnes RM, Kaasa S, et al: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years follow-up. J Clin Oncol 20:4665-4672, 2002
23. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
24. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
25. Pujol JL, Daures JP, Riviere A, et al: Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 93:300-308, 2001
26. Mavroudis D, Papadakis E, Veslemes M, et al: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12:463-470, 2001
27. Niell HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). J Clin Oncol 23:3752-3759, 2005
28. Tjan-Heijnen VCG, Wagener DJT, Postmus PE: An analysis of chemotherapy dose and dose-intensity in small cell lung cancer: Lessons to be drawn. Ann Oncol 13:1519-1530, 2002
29. Lorigan P, Woll PJ, O'Brien MER, et al: Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better prognosis small cell lung cancer. J Natl Cancer Inst 97:666-674, 2005
30. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327:1618-1624, 1992
31. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited stage small cell lung cancer. J Clin Oncol 10:890-895, 1992
32. Fried DB, Morris DE, Poole C, et al: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer: J Clin Oncol 22:4837-4845, 2004
33. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336-344, 1993
34. James LE, Spiro S, O'Donnell KM, et al: A randomized study of timing of thoracic irradiation in small cell lung cancer (SCLC): Study 8. Lung Cancer 41:S23, 2003 (suppl 2, abstr 0-69)
35. Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited stage small cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002
36. Komaki R, Swann RS, Ettinger DS, et al: Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62:342-350, 2005
37. Choi NC, Herndon II JE, Rosenman J, et al: Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated- accelerated twice-daily radiation schedules with concurrent chemotherapy for limited stage small cell lung cancer. J Clin Oncol 16:3528-3536, 1998
38. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 346:85-91, 2002
39. Hanna NH, Einhorn L, Sandler A, et al: Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive stage (ES) small cell lung cancer (SCLC). J Clin Oncol 23:1094, 2005 (suppl; abstr 7004)
40. Wakelee H, Kelly K: Novel approaches for the treatment of small cell lung cancer. Hematol Oncol Clin North Am 18:499-518, 2004